

Altus Pharmaceuticals Inc.
Form SC 13G/A
February 13, 2009

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G
(Rule 13d-102)

Information Statement Pursuant to Rules 13d-1 and 13d-2
Under the Securities Exchange Act of 1934
(Amendment No. 1)*

Altus Pharmaceuticals Inc.
(Name of Issuer)

Common Stock
(Title of Class of Securities)

02216N105
(CUSIP Number)

December 31, 2008
Date of Event Which Requires Filing of the Statement

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- Rule 13d-1(b)
- Rule 13d-1(c)
- Rule 13d-1(d)

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP
NO. 02216N105

13G

Page 2 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Investment Group, L.L.C.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware limited liability company

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER
		0
	6.	SHARED VOTING POWER
		4,484 shares
	7.	SOLE DISPOSITIVE POWER
		0
	8.	SHARED DISPOSITIVE POWER
		See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(1) as of December 31, 2008

12. TYPE OF REPORTING PERSON
OO; HC

Edgar Filing: Altus Pharmaceuticals Inc. - Form SC 13G/A

Based on 31,131,056 outstanding shares of the Common Stock of Issuer, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, as filed with the Securities and Exchange Commission on November 4, 2008.

CUSIP
NO. 02216N105

13G

Page 3 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Investment Group II, L.L.C.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited liability company

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(2) as of December 31, 2008

12. TYPE OF REPORTING PERSON
OO; HC

2 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 4 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Limited Partnership

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware limited partnership

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(3) as of December 31, 2008

12. TYPE OF REPORTING PERSON
PN; HC

3 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 5 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Kenneth Griffin

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
U.S. Citizen

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(4) as of December 31, 2008

12. TYPE OF REPORTING PERSON
IN; HC

4 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 6 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Holdings I LP

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited partnership

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(5) as of December 31, 2008

12. TYPE OF REPORTING PERSON
PN; HC

5 See footnote 1 above.

Page 6 of 16

CUSIP
NO. 02216N105

13G

Page 7 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Holdings II LP

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited partnership

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(6) as of December 31, 2008

12. TYPE OF REPORTING PERSON
PN; HC

6 See footnote 1 above.

Page 7 of 16

CUSIP
NO. 02216N105

13G

Page 8 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Advisors LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware limited liability company

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(7) as of December 31, 2008

12. TYPE OF REPORTING PERSON
OO; HC

7 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 9 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Derivatives Group LLC

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
(a) x
(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION
Delaware limited liability company

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5.	SOLE VOTING POWER 0
	6.	SHARED VOTING POWER 4,484 shares
	7.	SOLE DISPOSITIVE POWER 0
	8.	SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%⁽⁸⁾ as of December 31, 2008

12. TYPE OF REPORTING PERSON
OO; BD

8 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 10 of 16 Pages

1. NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Derivatives Trading Ltd.

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

(a) x

(b) o

3. SEC USE ONLY

4. CITIZENSHIP OR PLACE OF ORGANIZATION

Cayman Islands company

NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH	5. SOLE VOTING POWER 0
	6. SHARED VOTING POWER 4,484 shares
	7. SOLE DISPOSITIVE POWER 0
	8. SHARED DISPOSITIVE POWER See Row 6 above.

9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
See Row 6 above.

10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES
CERTAIN SHARES o

11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

Approximately 0.01%(9) as of December 31, 2008

12. TYPE OF REPORTING PERSON
CO

9 See footnote 1 above.

Page 10 of 16

CUSIP
NO. 02216N105

13G

Page 11 of 16 Pages

Item Name of Altus
1(a) Issuer: Pharmaceuticals
Inc.
Address of Issuer's Principal
1(b) Executive Offices:

333 Wyman
Street
Waltham,
Massachusetts
02451

Item Name of
2(a) Person
Filing(10)
Item Address of Principal
2(b) Business Office
Item Citizenship
2(c)

C i t a d e l
Investment
G r o u p ,
L.L.C.
1 3 1 S .
Dearborn
Street
32nd Floor
Chicago,
Illinois
60603
Delaware
l i m i t e d
l i a b i l i t y
company

C i t a d e l
Investment
Group II,
L.L.C.
1 3 1 S .
Dearborn
Street
32nd Floor
Chicago,
Illinois

60603
Delaware
limited
liability
company

C i t a d e l
L i m i t e d
P a r t n e r s h i p
1 3 1 S .
D e a r b o r n
S t r e e t
3 2 n d F l o o r
C h i c a g o ,
I l l i n o i s
6 0 6 0 3
D e l a w a r e
l i m i t e d
p a r t n e r s h i p

K e n n e t h
G r i f f i n
1 3 1 S .
D e a r b o r n
S t r e e t
3 2 n d F l o o r
C h i c a g o ,
I l l i n o i s
6 0 6 0 3
U . S .
C i t i z e n

C i t a d e l
H o l d i n g s I
L P
c / o C i t a d e l
I n v e s t m e n t
G r o u p I I ,
L . L . C .
1 3 1 S .
D e a r b o r n
S t r e e t
3 2 n d F l o o r
C h i c a g o ,
I l l i n o i s
6 0 6 0 3
D e l a w a r e
l i m i t e d
p a r t n e r s h i p

10 Citadel Derivatives Group LLC (“CDG”) is majority owned by Citadel Derivatives Group Investors, LLC, a Delaware limited liability company (“CDGI”). CDGI does not have control over the voting or disposition of securities held by CDG. Citadel Derivatives Trading Ltd. (“CDT”) is majority owned by CLP Holdings LLC, a Delaware limited liability company (“CLPH”). CLPH does not have control over the voting or disposition of securities held by CDT.

CUSIP
NO. 02216N105

13G

Page 12 of 16 Pages

C i t a d e l
Holdings II
LP
c/o Citadel
Investment
Group II,
L.L.C.
1 3 1 S .
Dearborn
Street
32nd Floor
Chicago,
Illinois
60603
Delaware
l i m i t e d
partnership

C i t a d e l
Advisors
LLC
c/o Citadel
Investment
Group II,
L.L.C.
1 3 1 S .
Dearborn
Street
32nd Floor
Chicago,
Illinois
60603
Delaware
l i m i t e d
liability
company

C i t a d e l
Derivatives
Group LLC
c/o Citadel
Investment
Group II,
L.L.C.
1 3 1 S .
Dearborn

Street
32nd Floor
Chicago,
Illinois
60603
Delaware
limited
liability
company

C i t a d e l
Derivatives
T r a d i n g
Ltd.
c/o Citadel
Investment
Group II,
L.L.C.
1 3 1 S .
Dearborn
Street
32nd Floor
Chicago,
Illinois
60603
C a y m a n
I s l a n d s
company

2(d) Title of Class of Securities:

Common Stock, par value \$0.01

2(e) CUSIP Number: 02216N105

Item 3 If this statement is filed pursuant to Rules 13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

- (a) Broker or dealer registered under Section 15 of the Exchange Act;
- (b) Bank as defined in Section 3(a)(6) of the Exchange Act;
- (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act;
- (d) Investment company registered under Section 8 of the Investment Company Act;
- (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
- (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F);

CUSIP
NO. 02216N105

13G

Page 13 of 16 Pages

- (g) o A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G);
- (h) o A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act;
- (i) o A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act;
- (j) o Group, in accordance with Rule 13d-1(b)(1)(ii)(J).

If this statement is filed pursuant to Rule 13d-1(c), check this box. x

Item 4 Ownership:

CITADEL
INVESTMENT
GROUP, L.L.C.
CITADEL
INVESTMENT
GROUP II,
L.L.C.
CITADEL
LIMITED
PARTNERSHIP
KENNETH
GRIFFIN
CITADEL
HOLDINGS I
LP
CITADEL
HOLDINGS II
LP
CITADEL
ADVISORS
LLC
CITADEL
DERIVATIVES
GROUP LLC
CITADEL
DERIVATIVES
TRADING LTD.

(a) Amount beneficially owned:

4,484 shares

(b) Percent of Class:

Approximately 0.01%(11) as of December 31, 2008

(c) Number of shares as to which such person has:

(i) sole power to vote or to direct the vote:

0

(ii) shared power to vote or to direct the vote:

See Item 4(a) above.

(iii) sole power to dispose or to direct the disposition of:

0

(iv) shared power to dispose or to direct the disposition of:

11 See footnote 1 above.

CUSIP
NO. 02216N105

13G

Page 14 of 16 Pages

See Item 4(a) above.

Item 5 Ownership of Five Percent or Less of a Class:

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: x

Item 6 Ownership of More than Five Percent on Behalf of Another Person:

Not Applicable.

Item 7 Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company:

See Item 2 above.

Item 8 Identification and Classification of Members of the Group:

Not Applicable.

Item 9 Notice of Dissolution of Group:

Not Applicable.

Item 10 Certification:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

* John C. Nagel is signing on behalf of Kenneth Griffin as attorney-in-fact pursuant to a power of attorney previously filed with the Securities and Exchange Commission on February 24, 2006, and hereby incorporated by reference herein. The power of attorney was filed as an attachment to a filing by Citadel Limited Partnership on Schedule 13G for Morgans Hotel Group Co.

CUSIP
NO. 02216N105

13G

Page 15 of 16 Pages

After reasonable inquiry and to the best of its knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

Dated this 13th day of February, 2009.

KENNETH GRIFFIN

CITADEL INVESTMENT GROUP, L.L.C.

By: /s/ John C. Nagel
John C. Nagel, attorney-in-fact*

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

CITADEL LIMITED PARTNERSHIP

CITADEL DERIVATIVES TRADING LTD.

By: Citadel Investment Group, L.L.C.,
its General Partner

By: Citadel Advisors LLC,
its Portfolio Manager

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

By: Citadel Holdings II LP,
its Sole Managing Member

CITADEL DERIVATIVES GROUP LLC

By: Citadel Investment Group II, L.L.C.,
its General Partner

By: Citadel Holdings I LP,
its Manager

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

By: Citadel Investment Group II, L.L.C.,
its General Partner

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

CITADEL INVESTMENT GROUP II, L.L.C.

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

CITADEL HOLDINGS I LP

By: Citadel Investment Group II, L.L.C.,
its General Partner

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

CUSIP
NO. 02216N105

13G

Page 16 of 16 Pages

CITADEL HOLDINGS II LP

CITADEL ADVISORS LLC

By: Citadel Investment Group II, L.L.C.,
its General Partner

By: Citadel Holdings II LP,
its Sole Managing Member

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

By: Citadel Investment Group II, L.L.C.,
its General Partner

By: /s/ John C. Nagel
John C. Nagel, Authorized Signatory

Page 16 of 16
